Profile data is unavailable for this security.
About the company
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
- Revenue in USD (TTM)0.00
- Net income in USD-18.21m
- Incorporated2014
- Employees14.00
- LocationImmix Biopharma Inc11400 West Olympic Blvd., Suite 200LOS ANGELES 90064United StatesUSA
- Phone+1 (310) 651-8041
- Websitehttps://immixbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 61.82m | 134.00 | 5.22 | 0.2473 | 1.89 | 0.24 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
Avrobio Inc | 0.00 | 30.31m | 62.40m | 13.00 | 2.01 | 0.7022 | 2.04 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Protara Therapeutics Inc | 0.00 | -42.47m | 63.62m | 26.00 | -- | 0.6049 | -- | -- | -3.74 | -3.74 | 0.00 | 5.11 | 0.00 | -- | -- | 0.00 | -48.67 | -37.02 | -52.23 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
Mural Oncology PLC | -100.00bn | -100.00bn | 63.63m | 117.00 | -- | 0.2708 | -- | -- | -- | -- | -- | 13.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
VolitionRX Ltd | 797.03k | -34.91m | 63.77m | 110.00 | -- | -- | -- | 80.02 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
Champions Oncology Inc | 49.22m | -9.73m | 63.89m | 230.00 | -- | -- | -- | 1.30 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
Lantern Pharma Inc | 0.00 | -17.53m | 64.88m | 21.00 | -- | 1.81 | -- | -- | -1.62 | -1.62 | 0.00 | 3.32 | 0.00 | -- | -- | 0.00 | -36.82 | -28.83 | -39.63 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
Immix Biopharma Inc | 0.00 | -18.21m | 65.22m | 14.00 | -- | 2.34 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
Celularity Inc | 14.79m | -181.41m | 65.35m | 225.00 | -- | 1.92 | -- | 4.42 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
enVVeno Medical Corp | 0.00 | -22.12m | 66.52m | 31.00 | -- | 1.57 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Intensity Therapeutics Inc | 0.00 | -15.13m | 67.04m | 5.00 | -- | 6.90 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
AN2 Therapeutics Inc | 0.00 | -64.73m | 67.71m | 41.00 | -- | 0.5414 | -- | -- | -2.82 | -2.82 | 0.00 | 4.19 | 0.00 | -- | -- | 0.00 | -53.65 | -- | -58.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 67.80m | 12.00 | -- | 3.97 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
AIGH Capital Management LLCas of 31 Mar 2024 | 1.56m | 5.89% |
Bleichroeder LPas of 31 Mar 2024 | 850.00k | 3.22% |
Cable Car Capital LLCas of 31 Mar 2024 | 670.46k | 2.54% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 456.19k | 1.73% |
Lynwood Capital Management, Inc.as of 31 Mar 2024 | 405.00k | 1.53% |
Renaissance Technologies LLCas of 31 Mar 2024 | 265.50k | 1.01% |
Geode Capital Management LLCas of 31 Mar 2024 | 124.77k | 0.47% |
Private Advisor Group LLCas of 31 Mar 2024 | 98.78k | 0.37% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 76.90k | 0.29% |
Corsair Capital Management LPas of 31 Mar 2024 | 69.39k | 0.26% |